{"contentid": 488043, "importid": NaN, "name": "Real-world Zolgensma data reinforces transformational profile", "introduction": "Swiss pharma giant Novartis has announced new data that reinforces the transformational benefit of Zolgensma (onasemnogene abeparvovec), a one-time gene therapy treatment for spinal muscular atrophy (SMA).", "content": "<p>Swiss pharma giant Novartis (NOVN: VX) has announced new data that reinforces the transformational benefit of Zolgensma (onasemnogene abeparvovec), a one-time gene therapy treatment for spinal muscular atrophy (SMA).</p>\n<p>Children with SMA treated pre-symptomatically achieved age-appropriate motor milestones including sitting, standing and walking, required no ventilatory or feeding tube support and had no serious, treatment-related adverse events.</p>\n<p><span class=\"pullQuote\">\"Consistent, significant and clinically meaningful therapeutic benefit in SMA\"</span>Real-world data indicate older children, aged from six months, achieved clinically-meaningful benefit with Zolgensma alone, after or in combination with another SMA therapy, with events consistent with the previously described safety profile.</p>\n<p>Zolgensma led to achievement of new milestones years after treatment in two long-term follow-up studies and resulted in sustained durability in children with SMA now up to six years old and more than five years post-treatment.</p>\n<p>To date, more than 1,000 children with SMA have been treated with Zolgensma across clinical trials, managed access programs, and in the commercial setting. It was approved in the USA in May 2019 and has subsequently has been authorized for use in 38 countries, with reimbursement already secured in some of those places.</p>\n<p>These data were presented during the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical and Scientific Conference.</p>\n<p>Shephard Mpofu, chief medical officer, Novartis Gene Therapies, said: &ldquo;With more than 1,000 patients now treated, these data presented at MDA further reinforce what we&rsquo;ve come to expect from Zolgensma &ndash; consistent, significant and clinically-meaningful therapeutic benefit in SMA, including prolonged event-free survival, achievement of motor milestones unseen in natural history of the disease, and durability now more than five years post-dosing.&rdquo;</p>\n<p>&nbsp;</p>", "date": "2021-03-15 15:00:00", "meta_title": NaN, "meta_keywords": "Zolgensma, data, benefit, reinforces, transformational, treatment, therapy, Novartis, muscular, gene, children, Real-world, profile, years, consistent, NOV", "meta_description": "Swiss pharma giant Novartis has announced new data that reinforces the transformational benefit of Zolgensma (onasemnogene abeparvovec), a one-time gene therapy", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-15 14:54:26", "updated": "2021-03-15 15:22:23", "access": NaN, "url": "https://www.thepharmaletter.com/article/real-world-zolgensma-data-reinforces-transformational-profile", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "novartis_tower_large.jpg", "image2id": "novartis_tower_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Spinal muscular atrophy", "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Rare diseases", "topic_tag": "Drug Trial, Real-world evidence, Research", "geography_tag": "USA", "company_tag": "Novartis", "drug_tag": "Zolgensma", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-15 15:00:00"}